Novel combination therapy for the eradication of Helicobacter pylori infection in a mouse model

Scandinavian Journal of Gastroenterology

Volumn 45, Issue 12, 2010, Pages 1424-1430

  Tran, Cuong D ^a,b   Kritas, Stamatiki ^a,b   Campbell, Mary A F ^a,b   Huynh, Hien Q ^c   Lee, Su San ^a   Butler, Ross N ^a,d  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c UNIVERSITY OF ALBERTA   (Canada)

^d UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

Amoxicillin; Eradication; Gastric emptying; Helicobacter pylori; Hyperimmune bovine colostrum; Mouse model; N acetyl cysteine; Novel therapy; Zinc

Indexed keywords

ACETYLCYSTEINE; AMOXICILLIN; ANTIINFECTIVE AGENT; HYPERIMMUNE BOVINE COLOSTRUM; OCTANOIC ACID C 13; OMEPRAZOLE; UNCLASSIFIED DRUG; ZINC;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL STRAIN; BACTERIUM CULTURE; BREATH ANALYSIS; COLOSTRUM; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; ERADICATION THERAPY; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; IN VIVO STUDY; INOCULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; STOMACH EMPTYING; TREATMENT DURATION; TUBE FEEDING;

ACETYLCYSTEINE; AMOXICILLIN; ANIMALS; ANTI-BACTERIAL AGENTS; CATTLE; COLOSTRUM; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; FEMALE; HELICOBACTER INFECTIONS; MICE; MICE, INBRED C57BL; TREATMENT OUTCOME; ZINC;

EID: 78649232896     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2010.506245     Document Type: Article

References (33)

1. Eslick GD. Helicobacter pylori infection causes gastric cancer? A review of the epidemiological, meta-analytic, and experimental evidence. World J Gastroenterol 2006;12:2991-9.
2. Pilotto A, Leandro G, Franceschi M, Bierti L, Di Battista R, Notarbartolo A, et al. Rapid improvement of symptomatology with pantoprazole, amoxycillin and metronidazole in Helicobacter pylori-positive duodenal ulcer patients. Hepatogastroenterology 1999;46:245-51.
3. De Boer WA. Topics in Helicobacter pylori infection: focus on a 'search-and-treat' strategy for ulcer disease. Scand J Gastroenterol Suppl 2000;232:4-9.
4. Marnila P, Rokka S, Rehnberg-Laiho L, Karkkainen P, Kosunen TU, Rautelin H, et al. Prevention and suppression of Helicobacter felis infection in mice using colostral preparation with specific antibodies. Helicobacter 2003;8:192-201.
5. Casswall TH, Nilsson HO, Bjorck L, Sjostedt S, Xu L, Nord CK, et al. Bovine anti-Helicobacter pylori antibodies for oral immunotherapy. Scand J Gastroenterol 2002;37:1380-5.
6. Casswall TH, Sarker SA, Albert MJ, Fuchs GJ, Bergstrom M, Bjorck L, et al. Treatment of Helicobacter pylori infection in infants in rural Bangladesh with oral immunoglobulins from hyperimmune bovine colostrum. Aliment Pharmacol Ther 1998;12:563-8.
7. Opekun AR, El-Zaimaity HM, Osato MS, Gilger MA, Malaty HM, Terry M, et al. Novel therapies for Helicobacter pylori infection. Aliment Pharmacol Ther 1999;13:35-42.
8. Huynh HQ, Couper RT, Tran CD, Moore L, Kelso R, Butler RN. N-acetylcysteine, a novel treatment for Helicobacter pylori infection. Dig Dis Sci 2004;49:1853-61.
9. Ziment I. Acetylcysteine: a drug with an interesting past and a fascinating future. Respiration 1986;50(Suppl 1):26-30.
10. Matthews GM, Butler RN. Cellular mucosal defense during Helicobacter pylori infection: a review of the role of glutathione and the oxidative pentose pathway. Helicobacter 2005;10:298-306.
11. Nishiwaki H, Kato S, Sugamoto S, Umeda M, Morita H, Yoneta T, et al. Ulcerogenic and healing impairing actions of monochloramine in rat stomachs: effects of zinc L-carnosine, polaprezinc. J Physiol Pharmacol 1999;50:183-95.
12. Tran CD, Campbell MA, Kolev Y, Chamberlain S, Huynh HQ, Butler RN. Short-term zinc supplementation attenuates Helicobacter felis-induced gastritis in the mouse. J Infect 2005;50:417-24.
13. Kashimura H, Suzuki K, Hassan M, Ikezawa K, Sawahata T, Watanabe T, et al. Polaprezinc, a mucosal protective agent, in combination with lansoprazole, amoxycillin and clarithromycin increases the cure rate of Helicobacter pylori infection. Aliment Pharmacol Ther 1999;13:483-7.
14. Lee A, O'Rourke J, De Ungria MC, Robertson B, Daskalopoulos G, Dixon MF. A standardized mouse model of Helicobacter pylori infection: introducing the Sydney strain. Gastroenterology 1997;112:1386-97.
15. Lee A, Fox JG, Otto G, Murphy J. A small animal model of human Helicobacter pylori active chronic gastritis. Gastroenterology 1990;99:1315-23.
16. Pacyna J, Siwek K, Terry SJ, Roberton ES, Johnson RB, Davidson GP. Survival of rotavirus antibody activity derived from bovine colostrum after passage through the human gastrointestinal tract. Pediatr Gastroenterol Nutr 2001;32:162-7.
17. Symonds E, Butler R, Omari T. Non-invasive breath tests can detect alterations in gastric emptying in the mouse. Eur J Clin Invest 2002;32:341-4.
18. Stolte M, Meining A. The updated Sydney system: classification and grading of gastritis as the basis of diagnosis and treatment. Can J Gastroenterol 2001;15:591-8.
19. Korhonen H, Syväoja EL, Ahola-Luttila H, Sivelä S, Kopola S, Husu J, et al. Bactericidal effect of bovine normal and immune serum, colostrum and milk against Helicobacter pylori. J Appl Bacteriol 1995;78:655-62.
20. Kashimura H, Suzuki K, Hassan M, Ikezawa K, Sawahata T, Watanabe T, et al. Polaprezinc, a mucosal protective agent, in combination with lansoprazole, amoxycillin and clarithromycin increases the cure rate of Helicobacter pylori infection. Aliment Pharmacol Ther 1999;13:483-7.
21. Troskot B, Simicevic VN, Dodig M, Rotkvic I, Ivankovic D, Duvnjak M. The protective effect of zinc sulphate pretreatment against duodenal ulcers in the rat. Biometals 1997;10:325-9.
22. Escolar G, Bulbena O. Zinc compounds, a new treatment in peptic ulcer. Drugs Exp Clin Res 1989;15:83-9.
23. Ravelli AM, Tobanelli P, Volpi S, Ugazio AG. Vomiting and gastric motility in infants with cow's milk allergy. J Pediatr Gastroenterol Nutr 2001;32:59-64.
24. Parkman HP, Urbain JL, Knight LC, Brown KL, Trate DM, Miller MA, et al. Effect of gastric acid suppressants on human gastric motility. Gut 1998;42:243-50.
25. Chiloiro M, Russo F, Riezzo G, Leoci C, Clemente C, Catrina M, et al. Effect of Helicobacter pylori infection on gastric emptying and gastrointestinal hormones in dyspeptic and healthy subjects. Dig Dis Sci 2001;46:46-53.
26. Duval-Araujo I, De Magal-Aes Queiroz D, Magnago A, Simal C, Marino VS, Carvalho S, et al. Increased gastric emptying induced by Helicobacter heilmannii type 1 infection in rats. J Med Microbiol 2000;49:627-34.
27. Domínguez-Munõz J, Malfertheiner P. Effect of Helicobacter pylori infection on gastrointestinal motility, pancreatic secretion and hormone release in asymptomatic humans. Scand J Gastroenterol 2001;36:1141-7.
28. Murakami K, Fujioka T, Shiota K, Ito A, Fujiyama K, Kodama R, et al. Influence of Helicobacter pylori infection and the effects of its eradication on gastric emptying in non-ulcerative dyspepsia. Eur J Gastroenterol Hepatol 1995;7: S93-7.
29. Debas H, Farooq O, Grossman M. Inhibition of gastric emptying is a physiological action of cholecystokinin. Gastroenterology 1975;68:1211-17.
30. Konturek J, Stoll R, Menzel J, Konturek M, Konturek S, Domschke W. Eradication of Helicobacter pylori restores the inhibitory effect of cholecystokinin on gastric motility in duodenal ulcer patients. Scand J Gastroenterol 2001;36:241-6.
31. Moran T, Wirth J, Schwartz G, McHugh P. Interactions between gastric volume and duodenal nutrients in the control of liquid gastric emptying. Am J Physiol 1999;76: R997-1002.
32. van der Schaar PJ, Straathof JW, Veenendaal RA, Lamers CB, Masclee AA. Does Helicobacter pylori gastritis affect motor function of proximal stomach in dyspeptic patients? Dig Dis Sci 2001;46:1833-8.
33. Stanghellini V, Barbara G, de Giorgio R, Tosetti C, Cogliandro R, Cogliandro L, et al. Helicobacter pylori, mucosal inflammation and symptom perception - new insights into an old hypothesis. Aliment Pharmacol Ther 2001;15(Suppl 1):28-32.